Symbols / PDSB $0.61 +12.77% PDS Biotechnology Corporation

Healthcare • Biotechnology • United States • NCM
PDSB Chart
About

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 33.11M
Enterprise Value 18.05M Income -34.88M Sales —
Book/sh 0.20 Cash/sh 0.54 Dividend Yield —
Payout 0.00% Employees 24 IPO —
P/E — Forward P/E -0.92 PEG —
P/S — P/B 3.06 P/C —
EV/EBITDA -0.56 EV/Sales — Quick Ratio 1.97
Current Ratio 2.09 Debt/Eq 190.06 LT Debt/Eq —
EPS (ttm) -0.74 EPS next Y -0.66 EPS Growth —
Revenue Growth — Earnings 2026-05-13 ROA -46.22%
ROE -221.81% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 54.72M
Shs Float 45.18M Short Float 3.82% Short Ratio 6.31
Short Interest — 52W High 1.92 52W Low 0.51
Beta 1.17 Avg Volume 603.03K Volume 838.32K
Target Price $9.00 Recom None Prev Close $0.54
Price $0.60 Change 12.77%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.00
Mean price target
2. Current target
$0.61
Latest analyst target
3. DCF / Fair value
$-5.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.61
Low
$3.00
High
$15.00
Mean
$9.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-25 main B. Riley Securities Buy → Buy $3
2025-11-13 main HC Wainwright & Co. Buy → Buy $15
2025-07-01 reit HC Wainwright & Co. Buy → Buy $13
2025-06-11 reit HC Wainwright & Co. Buy → Buy $13
2025-03-27 main HC Wainwright & Co. Buy → Buy $13
2025-03-13 reit HC Wainwright & Co. Buy → Buy $21
2025-03-07 reit HC Wainwright & Co. Buy → Buy $21
2025-02-24 reit HC Wainwright & Co. Buy → Buy $21
2024-12-18 reit HC Wainwright & Co. Buy → Buy $21
2024-11-25 main B. Riley Securities Buy → Buy $7
2024-11-15 reit HC Wainwright & Co. Buy → Buy $21
2024-10-24 reit HC Wainwright & Co. Buy → Buy $21
2024-10-02 reit HC Wainwright & Co. Buy → Buy $21
2024-09-17 reit HC Wainwright & Co. Buy → Buy $21
2024-08-20 main Alliance Global Partners Buy → Buy $7
2024-08-01 reit HC Wainwright & Co. Buy → Buy $21
2024-06-12 reit HC Wainwright & Co. Buy → Buy $21
2024-06-12 main B. Riley Securities Buy → Buy $9
2024-05-15 reit HC Wainwright & Co. Buy → Buy $21
2024-05-09 reit HC Wainwright & Co. Buy → Buy $21
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-02-28 FREITAG GREGORY GENE Director — 15,060 $1.33 $20,030
2025-02-28 GLOVER STEPHEN C Director — 15,061 $1.33 $20,031
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
36.32
-15.62%
43.05
+3.29%
41.67
+94.37%
21.44
Research And Development
22.57
-18.72%
27.76
-5.67%
29.43
+161.50%
11.25
Selling General And Administration
13.76
-9.99%
15.28
+24.84%
12.24
+20.19%
10.18
General And Administrative Expense
13.76
-9.99%
15.28
+24.84%
12.24
+20.19%
10.18
Other Gand A
13.76
-9.99%
15.28
+24.84%
12.24
+20.19%
10.18
Total Expenses
36.32
-15.62%
43.05
+3.29%
41.67
+94.37%
21.44
Operating Income
-36.32
+15.62%
-43.05
-3.29%
-41.67
-94.37%
-21.44
Total Operating Income As Reported
-36.32
+15.62%
-43.05
-3.29%
-41.67
-94.37%
-21.44
EBITDA
-33.79
+15.80%
-40.12
+1.50%
-40.74
-90.10%
-21.43
Normalized EBITDA
-33.79
+15.80%
-40.12
+1.50%
-40.74
-90.10%
-21.43
Reconciled Depreciation
0.02
+21.62%
0.02
+20084.88%
0.00
-98.39%
0.01
EBIT
-33.81
+15.78%
-40.14
+1.46%
-40.74
-90.05%
-21.43
Net Income
-37.61
+12.42%
-42.94
-5.11%
-40.85
-141.48%
-16.92
Pretax Income
-38.48
+13.23%
-44.35
-5.46%
-42.05
-96.19%
-21.43
Net Non Operating Interest Income Expense
-2.16
-65.65%
-1.30
-241.69%
-0.38
-8874.48%
0.00
Interest Expense Non Operating
4.67
+11.11%
4.21
+219.47%
1.32
0.00
Net Interest Income
-2.16
-65.65%
-1.30
-241.69%
-0.38
-8874.48%
0.00
Interest Expense
4.67
+11.11%
4.21
+219.47%
1.32
0.00
Interest Income Non Operating
2.51
-13.37%
2.90
+210.42%
0.94
+21418.18%
0.00
Interest Income
2.51
-13.37%
2.90
+210.42%
0.94
+21418.18%
0.00
Tax Provision
-0.87
+38.18%
-1.41
-17.28%
-1.20
+73.45%
-4.52
Tax Rate For Calcs
0.00
-28.13%
0.00
+10.34%
0.00
-86.26%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-37.61
+12.42%
-42.94
-5.11%
-40.85
-141.48%
-16.92
Net Income From Continuing Operation Net Minority Interest
-37.61
+12.42%
-42.94
-5.11%
-40.85
-141.48%
-16.92
Net Income From Continuing And Discontinued Operation
-37.61
+12.42%
-42.94
-5.11%
-40.85
-141.48%
-16.92
Net Income Continuous Operations
-37.61
+12.42%
-42.94
-5.11%
-40.85
-141.48%
-16.92
Normalized Income
-37.61
+12.42%
-42.94
-5.11%
-40.85
-141.48%
-16.92
Net Income Common Stockholders
-37.61
+12.42%
-42.94
-5.11%
-40.85
-141.48%
-16.92
Diluted EPS
-1.03
+25.90%
-1.39
+2.80%
-1.43
-116.67%
-0.66
Basic EPS
-1.03
+25.90%
-1.39
+2.80%
-1.43
-116.67%
-0.66
Basic Average Shares
36.45
+17.77%
30.95
+8.23%
28.60
+11.73%
25.60
Diluted Average Shares
36.45
+17.77%
30.95
+8.23%
28.60
+11.73%
25.60
Diluted NI Availto Com Stockholders
-37.61
+12.42%
-42.94
-5.11%
-40.85
-141.48%
-16.92
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
45.36
-23.63%
59.39
-22.88%
77.01
+14.60%
67.20
Current Assets
45.05
-23.71%
59.06
-22.78%
76.48
+14.42%
66.84
Cash Cash Equivalents And Short Term Investments
41.69
-26.29%
56.56
-23.38%
73.82
+13.15%
65.24
Cash And Cash Equivalents
41.69
-26.29%
56.56
-23.38%
73.82
+13.15%
65.24
Prepaid Assets
—
—
—
1.60
Other Current Assets
3.36
+34.89%
2.49
-6.23%
2.66
+66.52%
1.60
Total Non Current Assets
0.30
-9.19%
0.34
-36.50%
0.53
+47.48%
0.36
Net PPE
0.30
-9.19%
0.34
-36.50%
0.53
+47.48%
0.36
Gross PPE
0.46
-2.07%
0.47
-27.24%
0.64
+35.92%
0.47
Accumulated Depreciation
-0.15
-15.90%
-0.13
-15.04%
-0.12
-0.07%
-0.12
Properties
—
0.00
0.00
0.00
Buildings And Improvements
—
0.00
-100.00%
0.15
-57.32%
0.36
Machinery Furniture Equipment
0.03
+0.00%
0.03
+0.00%
0.03
+0.00%
0.03
Other Properties
0.43
-2.20%
0.44
-4.88%
0.46
+431.35%
0.09
Total Liabilities Net Minority Interest
26.35
-20.76%
33.26
+0.77%
33.01
+727.74%
3.99
Current Liabilities
17.09
+25.36%
13.63
+38.78%
9.82
+161.47%
3.76
Payables And Accrued Expenses
3.86
-52.42%
8.12
+5.49%
7.70
+277.46%
2.04
Payables
1.68
-75.87%
6.98
+472.70%
1.22
-6.88%
1.31
Accounts Payable
1.68
-75.87%
6.98
+472.70%
1.22
-6.88%
1.31
Current Accrued Expenses
2.18
+91.88%
1.14
-82.47%
6.48
+787.91%
0.73
Pensionand Other Post Retirement Benefit Plans Current
0.66
-48.56%
1.29
-29.81%
1.84
+25.99%
1.46
Current Debt And Capital Lease Obligation
12.56
+197.48%
4.22
+1365.92%
0.29
+11.25%
0.26
Current Debt
12.50
+200.00%
4.17
—
—
Other Current Borrowings
12.50
+200.00%
4.17
—
—
Current Capital Lease Obligation
0.06
+9.54%
0.06
-80.63%
0.29
+11.25%
0.26
Total Non Current Liabilities Net Minority Interest
9.27
-52.79%
19.63
-15.34%
23.18
+9918.09%
0.23
Long Term Debt And Capital Lease Obligation
9.27
-52.79%
19.63
-15.34%
23.18
+9918.09%
0.23
Long Term Debt
9.20
-52.81%
19.51
-15.27%
23.02
—
Long Term Capital Lease Obligation
0.06
-49.70%
0.12
-25.02%
0.16
-29.13%
0.23
Stockholders Equity
19.00
-27.27%
26.13
-40.61%
44.00
-30.39%
63.21
Common Stock Equity
19.00
-27.27%
26.13
-40.61%
44.00
-30.39%
63.21
Capital Stock
0.01
+14.79%
0.01
+9.69%
0.01
+6.06%
0.01
Common Stock
0.01
+14.79%
0.01
+9.69%
0.01
+6.06%
0.01
Share Issued
37.99
+14.78%
33.09
+9.69%
30.17
+6.05%
28.45
Ordinary Shares Number
37.99
+14.78%
33.09
+9.69%
30.17
+6.05%
28.45
Additional Paid In Capital
201.10
+17.87%
170.62
+17.22%
145.55
+17.47%
123.90
Retained Earnings
-182.11
-26.03%
-144.50
-42.28%
-101.56
-67.30%
-60.70
Total Equity Gross Minority Interest
19.00
-27.27%
26.13
-40.61%
44.00
-30.39%
63.21
Total Capitalization
28.21
-38.19%
45.64
-31.91%
67.02
+6.03%
63.21
Working Capital
27.97
-38.43%
45.43
-31.85%
66.66
+5.67%
63.08
Invested Capital
40.71
-18.26%
49.80
-25.69%
67.02
+6.03%
63.21
Total Debt
21.83
-8.49%
23.85
+1.61%
23.47
+4686.93%
0.49
Capital Lease Obligations
0.12
-31.21%
0.18
-60.45%
0.45
-7.81%
0.49
Net Tangible Assets
19.00
-27.27%
26.13
-40.61%
44.00
-30.39%
63.21
Tangible Book Value
19.00
-27.27%
26.13
-40.61%
44.00
-30.39%
63.21
Interest Payable
0.25
-17.75%
0.31
+9.41%
0.28
0.00
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-35.03
-4.14%
-33.64
-30.83%
-25.71
-105.91%
-12.49
Cash Flow From Continuing Operating Activities
-35.03
-4.14%
-33.64
-30.83%
-25.71
-105.91%
-12.49
Net Income From Continuing Operations
-37.61
+12.42%
-42.94
-5.11%
-40.85
-141.48%
-16.92
Depreciation Amortization Depletion
0.02
+21.62%
0.02
+20084.88%
0.00
-98.39%
0.01
Depreciation
0.02
+21.62%
0.02
+20084.88%
0.00
-98.39%
0.01
Depreciation And Amortization
0.02
+21.62%
0.02
+20084.88%
0.00
-98.39%
0.01
Other Non Cash Items
1.46
-21.94%
1.87
-65.77%
5.47
+2171.05%
0.24
Stock Based Compensation
6.85
-10.06%
7.61
+46.54%
5.20
+26.42%
4.11
Change In Working Capital
-5.75
-2786.31%
-0.20
-104.45%
4.47
+5802.27%
0.08
Change In Prepaid Assets
-0.87
-625.31%
0.17
+115.59%
-1.06
-963.68%
-0.10
Change In Payables And Accrued Expense
-4.88
-3790.24%
-0.13
-102.08%
6.04
+1641.65%
0.35
Change In Accrued Expense
0.42
+107.07%
-5.89
-196.13%
6.13
+1254.17%
0.45
Change In Payable
-5.30
-191.92%
5.76
+6495.69%
-0.09
+14.84%
-0.11
Change In Account Payable
-5.30
-191.92%
5.76
+6495.69%
-0.09
+14.84%
-0.11
Change In Other Current Assets
—
0.00
+100.00%
-0.42
0.00
Change In Other Current Liabilities
0.00
+100.00%
-0.24
-222.03%
-0.07
+56.47%
-0.17
Investing Cash Flow
-0.03
0.00
—
—
Cash Flow From Continuing Investing Activities
-0.03
0.00
—
—
Net PPE Purchase And Sale
-0.03
0.00
—
—
Purchase Of PPE
-0.03
0.00
—
—
Capital Expenditure
-0.03
—
—
—
Financing Cash Flow
20.19
+23.28%
16.38
-52.24%
34.29
-29.87%
48.89
Cash Flow From Continuing Financing Activities
20.19
+23.28%
16.38
-52.24%
34.29
-29.87%
48.89
Net Issuance Payments Of Debt
-3.18
-5263.90%
-0.06
-100.24%
25.00
0.00
Issuance Of Debt
—
0.00
-100.00%
25.00
0.00
Repayment Of Debt
-3.18
-5263.90%
-0.06
0.00
—
Long Term Debt Issuance
—
0.00
-100.00%
25.00
0.00
Long Term Debt Payments
-3.18
-5263.90%
-0.06
0.00
—
Net Long Term Debt Issuance
-3.18
-5263.90%
-0.06
-100.24%
25.00
0.00
Net Common Stock Issuance
22.60
+40.11%
16.13
+63.62%
9.86
-79.70%
48.54
Proceeds From Stock Option Exercised
0.77
+150.56%
0.31
+104.04%
0.15
-56.00%
0.34
Net Other Financing Charges
—
—
-0.72
—
Changes In Cash
-14.87
+13.84%
-17.26
-301.22%
8.58
-76.44%
36.40
Beginning Cash Position
56.56
-23.38%
73.82
+13.15%
65.24
+126.23%
28.84
End Cash Position
41.69
-26.29%
56.56
-23.38%
73.82
+13.15%
65.24
Free Cash Flow
-35.06
-4.23%
-33.64
-30.83%
-25.71
-105.91%
-12.49
Interest Paid Supplemental Data
3.56
+0.61%
3.54
+314.81%
0.85
0.00
Common Stock Issuance
22.60
+40.11%
16.13
+63.62%
9.86
-79.70%
48.54
Issuance Of Capital Stock
22.60
+40.11%
16.13
+63.62%
9.86
-79.70%
48.54
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category